← board
CYCN
distress 4/10 · elevated risk$3.63-2%today-43% from 52w high
Lead: treatment-resistant depression · est. market ~$16B (approx, global)
Revenue
pre-revenue
Liquidity
$3M
Runway
0.6 yrs
Shares 1y
+30%
Price & events
+163.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
-2.2%
1W
+12.7%
1M
+18.6%
3M
+163.0%
6M
+13.8%
1Y
+8.4%
2Y
-95.0%
5Y
-94.0%
All
Overview
- Market Cap
- $15.72M
- Volume
- 11.40K
- 52 Week Range
- $1.08 – $6.38
- Total Shares
- 4.33M
- Float Shares
- 3.14M
- Short %
- 1.39%
- % Held by Insiders
- 25.28%
- % Held by Institutions
- 4.32%
- RVOL
- 0.46x
- Beta
- 1.75
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 10
- in 2027Guided 40%readoutPhase 2TRD therapy · Initial data set anticipatedSEC 8-K
- in 2026Guided 40%trial initiationsecondaryPhase 2TRD therapy · Phase 2 proof-of-concept trial expected to initiateSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 2Praliciguat · Initiation of Phase 2 clinical trial for FSGS; first patient dosing expected in 2026.SEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 2CYC-126 · initiate Phase 2 proof-of-concept studySEC 8-K
- 2026-04-01partnershipEntered into merger agreement with KorsanaSEC 8-K
- 2026-02-17fda agreementCYC-126 · Received positive pre-IND written feedback from FDA on Phase 2 study design and regulatory pathSEC 8-K
- 2026-01-03partnershipCYC-126 · entered into option-to-license collaboration with Medsteer for closed-loop anesthetic delivery systemSEC 8-K
- 2025-09-19partnershipTRD therapy · Entered into exclusive worldwide license with MIT for neuropsychiatric disordersSEC 8-K
- 2024-12-13partnershipolinciguat · Entered exclusive license option agreement with CVCO Therapeutics.SEC 8-K
- 2024-12-13partnershippraliciguat · Amended license with Akebia for $1.75M upfront and near-term payments, increased royalties.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — treatment-resistant depression
Recent news
- 2026-07-23Brookaire commercial air filtration company unveils new - GlobeNewswire
- 2026-07-22Cyclerion Therapeutics (CYCN) plans merger with Korsana and $380M financing - Stock Titan
- 2026-07-22Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 - Business Wire
- 2026-07-21Form 13D/A CYCLERION THERAPEUTICS For: 21 July By Investing.com - Investing.com South Africa
- 2026-07-21Form 13D/A CYCLERION THERAPEUTICS For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-20Cyclerion Therapeutics (CYCN) investor reports 19.4% stake and preferred share conversion - Stock Titan
- 2026-07-20Cyclerion Therapeutics (CYCN) director converts 351,037 preferred to common shares - Stock Titan
- 2026-07-17Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beats Estimates as Pre-Revenue Biotech Tightens Cost Control - Profit Recovery Report - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.